SPECCHIO
Device Facts
| Record ID | K260647 |
|---|---|
| Device Name | SPECCHIO |
| Applicant | El.En S.P.A. |
| Product Code | PBX · General, Plastic Surgery |
| Decision Date | Apr 2, 2026 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 878.4400 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The SPECCHIO RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The SPECCHIO massage device is intended to provide a temporary reduction in the appearance of cellulite.
Device Story
SPECCHIO is a medical radio frequency (RF) and massage device used by clinicians in a professional setting. It utilizes high-frequency (2.45 GHz) bipolar RF currents to induce localized subcutaneous tissue heating (40-43°C) for pain relief, muscle spasm reduction, and increased local circulation. Integrated massaging handpieces provide mechanical stimulation for temporary cellulite reduction. The system includes three handpieces (Deep PRO, Shallow PRO, Pocket PRO) with AISI 316 material heads. The operator controls the device via a GUI; the system features a contact quality monitoring system to ensure safe energy delivery. By elevating tissue temperature, the device aims to provide therapeutic relief and aesthetic improvement. It is a modified version of the DEKA TIAC II, featuring updated chassis, GUI, and handpiece profiling.
Clinical Evidence
No clinical data provided. Bench testing only: ex-vivo animal tissue studies demonstrated the device maintains tissue temperature between 40°C-43°C for at least 5 minutes at maximum RF output power. Skin surface temperature maintenance (40°-45°C for 10 minutes) was verified using the same methodology as the predicate device.
Technological Characteristics
RF energy source (2.45 GHz, 200W, bipolar). Handpieces utilize AISI 316 stainless steel. Dimensions: Deep PRO (66mm), Shallow PRO (56mm), Pocket PRO (36.5mm). Electrical: 100-240V, 50/60Hz, 1500VA. Includes contact quality monitoring system. Standards: ANSI AAMI ES60601-1, IEC 60601-1-2, IEC 60601-2-6.
Indications for Use
Indicated for adults (22 years and older) for temporary relief of pain, muscle spasms, increased local circulation via RF heating, and temporary reduction in the appearance of cellulite via massage.
Regulatory Classification
Identification
An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.
Predicate Devices
- DEKA TIAC II (K211091)
Submission Summary (Full Text)
{0}
FDA U.S. FOOD & DRUG ADMINISTRATION
April 2, 2026
El.En S.P.A.
Peruzzi Paolo
Regulatory Affairs Manager
Contact Address
Re: K260647
Trade/Device Name: SPECCHIO
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical Cutting And Coagulation Device And Accessories
Regulatory Class: Class II
Product Code: PBX
Dated: [NOTE: Use date of most recent supplement]
Received: March 6, 2026
Dear Peruzzi Paolo:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{1}
K260647 - Peruzzi Paolo
Page 2
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
{2}
K260647 - Peruzzi Paolo
Page 3
Sincerely,
JAMES H. JANG-S
Digitally signed by
JAMES H. JANG-S
Date: 2026.04.02
16:38:20 -04'00"
James Jang, Ph.D.
Acting Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical and
Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{3}
| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260647 | ? |
| Please provide the device trade name(s). | | ? |
| SPECCHIO | | |
| Please provide your Indications for Use below. | | ? |
| The SPECCHIO RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The SPECCHIO massage device is intended to provide a temporary reduction in the appearance of cellulite. | | |
| Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? |
| Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old)
☐ Infants (29 days old to < 2 years old)
☐ Children (2 years old to < 12 years old)
☐ Adolescents (12 years old to < 22 years old)
☑ Adults (22 years old and greater) | ? |
{4}
K260647
# 510(k) Summary
## SPECCHIO – Special 510(k)
### Submitter:
El.En. S.p.A.
Via Baldanzese, 17
50041 Calenzano (FI), Italy
### Contact:
Paolo Peruzzi
Regulatory Affairs Manager & Official Correspondent
Phone: +39.055.8826807
E-mail: p.peruzzi@elen.it
### Date Summary Prepared:
February 27th, 2026
### Device Trade Name:
SPECCHIO
### Common Name:
Medical radio frequency and massage device
### Regulation Number:
21 CFR 878.4400
### Regulation Name:
Electrosurgical cutting and coagulation device and accessories
### Regulatory Class:
Class II
### Product Code:
PBX
### Predicate Device:
DEKA TIAC II (K211091)
### Device Description:
The SPECCHIO is a medical device that used high frequency RF currents to produce a localized increase in temperature in subcutaneous tissue, for temporary relief of pain and muscle spasm and increase local
{5}
K260647
circulation. The device has integrated massaging handpieces intended to provide a temporary reduction in the appearance of cellulite.
The SPECCHIO device electrical specifications are: 100-240V~, 50/60Hz, 1500VA.
The proposed SPECCHIO is a modification of DEKA TIAC II device (K211091)
The modifications to the cleared device are:
- Restyling of the device (chassis, cover plastics and GUI)
- Engineering of the Shallow and Deep handpieces (colour change, profiling and interchangeability of massage head)
- Addition of Pocket PRO handpiece
The technical specifications are within the range of the already cleared predicate device DEKA TIAC II (K211091)
The indications for use of the modified device are unchanged with respect to the predicate device. Labelling itself has been updated also to include general improvements that have been implemented since predicate device clearance and considered as minor changes.
## Indications for Use:
The SPECCHIO RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The SPECCHIO massage device is intended to provide a temporary reduction in the appearance of cellulite.
## Comparison with the Predicate Device:
The SPECCHIO device is as safe, as effective, and performs as well as the legally marketed predicate device DEKA TIAC II (K211091).
| Device Trade Name | Subject Device
SPECCHIO | Predicate Device
K211091
DEKA TIAC II | Comment |
| --- | --- | --- | --- |
| Indications for use | The SPECCHIO RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The SPECCHIO massage device is intended to provide a temporary reduction in the appearance of cellulite. | The DEKA TIACII RF device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The DEKA TIAC II massage device is intended to provide a temporary reduction in the appearance of cellulite. | Identical |
| Regulation Number | 21 CFR 878.4400: Electrosurgical cutting and coagulation | 21 CFR 878.4400: Electrosurgical cutting and coagulation | Identical |
| Product Code | PBX | PBX | Identical |
| Device Technologies | Application of the heat to the tissue via RF energy. | Application of the heat to the tissue via RF energy. | Identical |
{6}
K260647
| Device Trade Name | Subject Device
SPECCHIO | Predicate Device
K211091
DEKA TIAC II | Comment |
| --- | --- | --- | --- |
| | Mechanical Massaging of body parts | Mechanical Massaging of body parts | |
| Maximum RF output power | 200W | 200W | Identical |
| RF mode of operation | Bipolar | Bipolar | Identical |
| RF Output Frequency | 2.45 GHz | 2.45 GHz | Identical |
| Effective temperature | 40-43°C | 40-43°C | Identical |
| Contact quality monitoring system | YES | YES | Identical |
| Handpieces | Deep PRO Handpiece (66 mm)
Shallow PRO Handpiece (56 mm)
Pocket PRO Handpiece (36.5 mm) | Deep Handpiece (78 mm)
Shallow handpiece (68 mm) | Similar
Differences do not affect safety and efficacy |
| Massage handpiece dimensions | 68 mm | Handpiece 1: Diameter: 68 mm
Handpiece 2: Diameter: 78 mm | Subset |
| Massage handpiece material | AISI 316 | AISI 316 | Identical |
## Clinical Performance Data:
Clinical performance tests, in order to demonstrate that SPECCHIO RF device is capable of maintaining a skin surface temperature of 40°-45°C for at least 10 minutes when using the device as intended (same test method used for the predicate device).
## Non-Clinical Performance Data:
### Electrical safety and electromagnetic compatibility (EMC)
Electrical safety and EMC testing were conducted on the SPECCHIO device, according to the following standards:
- ANSI AAMI ES60601-1 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance.
- IEC 60601-1-2 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests.
{7}
K260647
- Test according to IEC 60601-2-6:2012+A1:2016- Medical electrical equipment - Part 2-6: Particular requirements for basic safety and essential performance of microwave therapy equipment.
- Non-clinical performance tests on ex-vivo animal tissue, in order to show that SPECCHIO RF device is able to maintain the tissue temperature in the range 40°C - 43°C for at least 5 minutes, at the maximum setting of RF output power (same test method used for the predicate device).
## Software Validation and Verification Testing
Software verification and validation testing were conducted and documented as recommended by FDA’s Guidance for Industry and FDA Staff, “Content of Premarket Submissions for Device Software Functions”.
## Conclusion:
On the basis of the comparison with the predicate devices and on the non-clinical performance data, we can conclude that SPECCHIO device is deemed to be substantially equivalent to the predicate device for the proposed indications for use.
## Additional Information:
None.
